Zoetis Inc. (NYSE:ZTS) Position Raised by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 16.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,150 shares of the company's stock after purchasing an additional 6,214 shares during the period. Crossmark Global Holdings Inc.'s holdings in Zoetis were worth $7,105,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. HUB Investment Partners LLC increased its holdings in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its holdings in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares in the last quarter. Ironwood Investment Management LLC increased its holdings in Zoetis by 0.8% in the 4th quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock valued at $1,361,000 after purchasing an additional 68 shares in the last quarter. Legacy Financial Advisors Inc. grew its stake in shares of Zoetis by 5.8% during the fourth quarter. Legacy Financial Advisors Inc. now owns 1,282 shares of the company's stock valued at $209,000 after acquiring an additional 70 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. grew its stake in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after acquiring an additional 73 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.5%

NYSE:ZTS traded up $0.77 during mid-day trading on Thursday, reaching $159.04. The stock had a trading volume of 2,280,740 shares, compared to its average volume of 2,583,343. The company has a market capitalization of $70.81 billion, a price-to-earnings ratio of 28.55, a price-to-earnings-growth ratio of 2.62 and a beta of 0.91. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The stock's 50 day simple moving average is $161.30 and its two-hundred day simple moving average is $161.97. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period last year, the firm earned $1.38 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.26%. Zoetis's dividend payout ratio is currently 35.91%.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of "Buy" and an average price target of $212.13.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.